Marvel Biosciences Corp. reported earnings results for the second quarter and six months ended January 31, 2024. For the second quarter, the company reported net loss was CAD 0.232814 million compared to CAD 0.232991 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago.
For the six months, net loss was CAD 0.751112 million compared to CAD 0.529195 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.01 a year ago.